Skip to content
OpenCapital
Get started

Pfizer PFE Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%

Valuation

See full
Market cap$134.91B-1.0%
Enterprise value$197.57B+0.7%
P/E11.1×—
P/S2.1×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Calculated from Pfizer’s reported figures.

$2.6Bnet cash from operating−$436.0Mcapital expenditures=$2.18B

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's free cash flow?
Pfizer (PFE) reported free cash flow of $2.18B in Q1 2026.
How has Pfizer's free cash flow changed year-over-year?
Pfizer's free cash flow increased by 23.0% year-over-year, from $1.77B to $2.18B.
What is the long-term trend for Pfizer's free cash flow?
Over 3 years (2021 to 2024), Pfizer's free cash flow has grown at a -30.9% compound annual growth rate (CAGR), from $29.87B to $9.84B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.